Kinetics of immune suppressant use after transplantation. (A) Cumulative incidence of terminating cyclosporine A and FK506. The values on day 180 were 40% (95% CI, 28%-52%) among CB transplant recipients and 16% (95% CI, 5%-26%) among BM transplant recipients. Panel B shows the cumulative incidence of acute GVHD grades III to IV. The values for grades III and IV acute GVHD on day 100 were 6% (95% CI, 0%-19%) for CBT and 27% (95% CI, 15%-42%) for BMT. (C) Estimated cumulative incidences of requiring steroid therapy in patients after CBT and BMT.